Jesus Zapata
Nurse Practitioner · San Antonio, TXNPI 1699449801
Payments from drug & device makers
Across 77 payments — averaging $55.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$2K
- AstraZeneca$229
- Merck$185
- Boehringer Ingelheim$176
- Scpharmaceuticals Inc.$155
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$153
- plus $1K from 15 others
What the payments were for
- Travel & lodging$1,18628%
- Food & beverage$3,06672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 25 | $2,334 |
| AstraZeneca(2 entities) | 4 | $229 |
| Merck | 6 | $185 |
| Boehringer Ingelheim | 3 | $176 |
| Scpharmaceuticals Inc. | 2 | $155 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $153 |
| Abiomed | 1 | $150 |
| Alnylam Pharmaceuticals Inc. | 5 | $126 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Novartis | 6 | $119 |
| United Therapeutics Corporation | 4 | $83 |
| Novo Nordisk | 2 | $54 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Pfizer | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Sandoz | 1 | $25 |
| Bayer | 1 | $25 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,252 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 53 | $48,028 |
| EliquisApixaban | 35 | $32,700 |
| EntrestoSacubitril/Valsartan | 19 | $17,349 |
| Tacrolimus | 16 | $5,421 |
| Torsemide | 123 | $1,862 |
| Potassium Chloride | 81 | $1,609 |
| Midodrine Hcl | 11 | $567 |
| Bumetanide | 20 | $548 |
| Metoprolol Succinate | 50 | $239 |
| Gabapentin | 23 | $220 |
| Amiodarone Hcl | 27 | $216 |
| ClopidogrelClopidogrel Bisulfate | 37 | $198 |
| Spironolactone | 53 | $187 |
| Carvedilol | 19 | $182 |
| Warfarin Sodium | 19 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $229 | $48,02853 claims |
| PfizerEliquis | $34 | $32,70035 claims |
| NovartisEntresto | $119 | $17,34919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in San Antonio
- Corrie BerkSan Antonio$155K
- Sonja BruneSan Antonio$51K
- Laura GalvanSan Antonio$32K
- Eduardo GonzalezSan Antonio$32K
- Roberta RomeroSan Antonio$26K
- Christopher GarciaSan Antonio$21K
- Jennifer ZavalaSan Antonio$17K
- Amy RivasSan Antonio$17K
- Erika SimpsonSan Antonio$16K
- Alexis WahlenSan Antonio$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.